Processa Pharmaceuticals, Inc., a pharmaceutical company, engages in the clinical development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet for the treatment of necrobiosis lipoidica and radiation-induced fibrosis in head and neck cancer patients. The company is based in Hanover, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone443-776-3133
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Processa Pharmaceuticals (OTCMKTS:PCSA) Frequently Asked Questions
What is Processa Pharmaceuticals' stock symbol?
Processa Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PCSA."
How were Processa Pharmaceuticals' earnings last quarter?
When is Processa Pharmaceuticals' next earnings date?
Has Processa Pharmaceuticals been receiving favorable news coverage?
Media headlines about PCSA stock have trended positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Processa Pharmaceuticals earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Processa Pharmaceuticals.
Who are some of Processa Pharmaceuticals' key competitors?
Some companies that are related to Processa Pharmaceuticals include Magenta Therapeutics (MGTA), Avedro (AVDR), Arcus Biosciences (RCUS), Merus (MRUS), AMAG Pharmaceuticals (AMAG), Syros Pharmaceuticals (SYRS), BioSpecifics Technologies (BSTC), DURECT (DRRX), XBiotech (XBIT), Obseva (OBSV), Lexicon Pharmaceuticals (LXRX), Kiniksa Pharmaceuticals (KNSA), Innate Pharma (IPHYF), ImmunoGen (IMGN) and Kadmon (KDMN).
Who are Processa Pharmaceuticals' key executives?
Processa Pharmaceuticals' management team includes the folowing people:
- Dr. David Young, Co- Founder, Chairman & CEO (Age 66)
- Mr. Patrick Lin, Co-Founder, Chief Bus. & Strategy Officer and Director (Age 54)
- Dr. Sian E. Bigora, Co-Founder & Chief Devel. Officer (Age 59)
- Ms. Wendy Guy, Co-Founder & Chief Admin. Officer (Age 55)
- Mr. James H. Stanker, Chief Financial Officer (Age 61)
How do I buy shares of Processa Pharmaceuticals?
Shares of PCSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Processa Pharmaceuticals' stock price today?
One share of PCSA stock can currently be purchased for approximately $2.50.
How big of a company is Processa Pharmaceuticals?
What is Processa Pharmaceuticals' official website?
How can I contact Processa Pharmaceuticals?
Processa Pharmaceuticals' mailing address is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. The company can be reached via phone at 443-776-3133 or via email at [email protected]
MarketBeat Community Rating for Processa Pharmaceuticals (OTCMKTS PCSA)
MarketBeat's community ratings are surveys of what our community members think about Processa Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
